<?xml version="1.0" encoding="UTF-8"?>
<p id="P24">Foscarnet is a nonnucleoside pyrophosphate analogue that is given intravenously for the treatment of herpesviruses.
 <sup>
  <xref ref-type="bibr" rid="R58">58</xref>
 </sup> Its pharmacokinetic profile is complicated by a high incidence of nephrotoxicity and by its deposition and subsequent gradual release from bone.
 <sup>
  <xref ref-type="bibr" rid="R58">58</xref>
 </sup> Its half-life depends on the duration of therapy; in patients with normal renal function, the plasma half-life is about 2 to 4 hours, but terminal half-lives up to about 8 days may occur when it has accumulated in bones. Foscarnet is excreted through glomerular filtration.
</p>
